<p>Cencora, Inc.（纽约证券交易所：COR - 获取免费报告）的股价在周五的午盘交易中创下了新的 52 周高点，此前富国银行将他们对该股的目标价从 236.00 美元上调至 249.00 美元。富国银行目前对该股持有等权重评级。Cencora 的股价最高达到 247.66 美元，最后交易价为 247.57 美元，成交量为 3243856 股。该股之前收盘价为 244.46 美元。</p>
<ul>
<li>Teva Pharma 是参与仿制药复兴的方式</li>
</ul>
<p>COR 已成为多份研究报告的主题。StockNews.com 在 5 月 2 日星期四的一份研究报告中，将 Cencora 的股票评级从 “强烈买入” 下调为 “买入”。花旗集团将 Cencora 的目标股价从 265.00 美元上调至 280.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 将 Cencora 的目标股价从 285.00 美元上调至 287.00 美元，并给予该公司 “表现优异” 评级。最后，SVB Leerink 重申了对 Cencora 的 “表现优异” 评级，并在 6 月 27 日星期四的一份研究报告中发布了 275.00 美元的目标股价。三位研究分析师对该股给予持有评级，七位分析师给予该公司股票买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “中等买入”，平均目标股价为 243.00 美元。</p>
<p><strong>查看我们关于 Cencora 的最新研究报告</strong></p>
<h2>Cencora 内部交易</h2>
<ul>
<li>艾礼礼、麦克森、诺华股价表现良好</li>
</ul>
<p>另外，董事 Dermot Mark Durcan 于 5 月 24 日星期五进行了一笔交易，购入了 500 股该公司的股票。这些股票的平均成本为每股 218.58 美元，总交易额为 109,290.00 美元。购买后，该董事现在持有公司股票的 21,876 股，价值约 4,781,656.08 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此链接查看。此外，首席执行官 Steven H. Collis 于 7 月 16 日星期二出售了公司股票的 10,755 股。股票的平均价格为 222.12 美元，总交易额为 2,388,900.60 美元。出售后，首席执行官在公司中直接持有 285,088 股股票，价值 63,323,746.56 美元。该销售已在提交给证券交易委员会的文件中披露，可在此链接查看。此外，董事 Dermot Mark Durcan 于 5 月 24 日星期五购入了公司股票的 500 股。这些股票的平均价格为每股 218.58 美元，总交易额为 109,290.00 美元。交易完成后，该董事现在持有公司股票的 21,876 股，价值 4,781,656.08 美元。有关此次购买的披露信息，请点击此处。在过去的三个月中，内部人士已出售了价值 408,654,376 美元的 1,899,112 股公司股票。公司内部人士持有公司股票的比例为 15.80%。</p>
<h2>机构投资者对 Cencora 的看法</h2>
<p>对冲基金和其他机构投资者最近调整了他们对该股的持股。Fisher Asset Management LLC 在第四季度购入了 Cencora 股票的新头寸，价值约 244,000 美元。Vermont 信托公司在第四季度购入了 Cencora 股票的新头寸，价值约 62,000 美元。Wahed Invest LLC 在第四季度购入了 Cencora 股票的新头寸，价值约 567,000 美元。Vanguard Group Inc.在第四季度购入了 Cencora 股票的新头寸，价值约 4,212,508,000 美元。最后，Hennessy Advisors Inc.在第四季度购入了 Cencora 股票的新头寸，价值约 3,307,000 美元。目前，97.52% 的股份由机构投资者持有。</p>
<h2>Cencora 股票表现</h2>
<ul>
<li>3 家高股息房地产投资信托公司备受分析师看好</li>
</ul>
<p>该公司的市值为 493.8 亿美元，市盈率为 26.74，PEG 比率为 1.65，贝塔系数为 0.45。公司的 50 日移动平均价格为 228.28 美元，其两百日移动平均价格为 230.99 美元。公司的速动比率为 0.53，流动比率为 0.89，负债权益比率为 3.41。</p>
<p>Cencora（纽约证券交易所：COR - 获取免费报告）于 7 月 31 日星期三发布了最新的财报。该公司报告季度每股收益为 3.34 美元，超过了每股 3.18 美元的共识预期。该季度业务收入为 742.0 亿美元，而分析师预计为 733.2 亿美元。Cencora 的净资产回报率为 271.72%，净利润率为 0.65%。该季度 Cencora 的营收同比增长了 10.8%。在去年同期的同一季度，该公司每股收益为 2.92 美元。股票分析师预计，Cencora, Inc.在本财年将实现每股 13.47 美元的盈利。</p>
<h2>Cencora 股息宣布</h2>
<p>该公司最近宣布了季度股息，将于 8 月 26 日星期一支付。股东记录日期为 8 月 9 日星期五，将支付 0.51 美元的股息。这代表了每年 2.04 美元的股息和 0.82% 的收益率。该股息的除息日为 8 月 9 日星期五。Cencora 的股息支付比率目前为 22.32%。</p>
<h2>Cencora 公司简介（获取免费报告）</h2>
<p>Cencora, Inc 是一家从事药品采购和分销的公司。该公司的美国医疗解决方案部门向急救医院、健康系统、独立和连锁零售药店、邮购药店、医疗诊所、长期护理和其他客户分发药品、非处方健康产品、家庭医疗用品和设备，以及相关服务；提供药房管理、人员配备和其他咨询服务；为零售和机构医疗服务提供供应管理软件；为各种机构和零售医疗服务提供包装解决方案；为生物技术和制药制造商提供临床试验支持、产品后批准和商业化支持服务、数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断试剂、微量饲料成分和其他产品；以及向制造商提供销售人员服务。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们比 Cencora 更喜欢的股票</li>
<li>房地产投资信托股票 - 今日应添加到您的投资组合中的最佳房地产投资信托股票</li>
<li>您应该投资比特币吗？利弊</li>
<li>投资于 5G 技术的热门股票</li>
<li>亚马逊股票在 AI 泡沫破裂后有望强劲反弹</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>壳牌股票：石油和天然气巨头致力于回购和派息</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 揭秘：英伟达的&#34;秘密版税&#34;计划（来自市场幕后）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDM5"/></p>
<h2>您现在是否应该投资$1,000 美元到 Cencora？</h2>
<p>在考虑投资 Cencora 之前，您应该听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票... 而 Cencora 不在这个名单上。</p>
<p>尽管 Cencora 目前在分析师中有一个&#34;中等买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Cencora（NYSE：COR）在富国银行的分析师升级后达到了新的 12 个月高点。股价最高达到 247.66 美元，并以 247.57 美元收盘。其他几份报告也给予 Cencora 正面评级，并提高了其股价目标。该公司的市值为 493.8 亿美元，市盈率为 26.74。公司上季度每股收益为 3.34 美元，超过了分析师的预期。目前该股被评为 “中等买入”，平均目标价为 243.00 美元</p>

<p>Cencora, Inc. (NYSE:COR - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday after Wells Fargo &amp; Company raised their price target on the stock from $236.00 to $249.00. Wells Fargo &amp; Company currently has an equal weight rating on the stock. Cencora traded as high as $247.66 and last traded at $247.57, with a volume of 3243856 shares. The stock had previously closed at $244.46.</p>
<ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><p>Cencora, Inc.（纽约证券交易所：COR - 获取免费报告）的股价在周五的午盘交易中创下了新的 52 周高点，此前富国银行将他们对该股的目标价从 236.00 美元上调至 249.00 美元。富国银行目前对该股持有等权重评级。Cencora 的股价最高达到 247.66 美元，最后交易价为 247.57 美元，成交量为 3243856 股。该股之前收盘价为 244.46 美元。</p>
<ul>
<li>Teva Pharma 是参与仿制药复兴的方式</li>
</ul>
</div><p>COR has been the topic of several other reports. StockNews.com downgraded shares of Cencora from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Thursday, May 2nd. Citigroup lifted their price objective on shares of Cencora from $265.00 to $280.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, April 30th. Robert W. Baird lifted their price objective on shares of Cencora from $285.00 to $287.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday. Finally, SVB Leerink reiterated an &#34;outperform&#34; rating and issued a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $243.00.</p>
<div class="lb-trans"><p>COR 已成为多份研究报告的主题。StockNews.com 在 5 月 2 日星期四的一份研究报告中，将 Cencora 的股票评级从 “强烈买入” 下调为 “买入”。花旗集团将 Cencora 的目标股价从 265.00 美元上调至 280.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 将 Cencora 的目标股价从 285.00 美元上调至 287.00 美元，并给予该公司 “表现优异” 评级。最后，SVB Leerink 重申了对 Cencora 的 “表现优异” 评级，并在 6 月 27 日星期四的一份研究报告中发布了 275.00 美元的目标股价。三位研究分析师对该股给予持有评级，七位分析师给予该公司股票买入评级。根据 MarketBeat.com 的数据，该股目前的平均评级为 “中等买入”，平均目标股价为 243.00 美元。</p>
</div><p><strong>View Our Latest Research Report on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Cencora 的最新研究报告</strong></p>
</div><h2>Insider Activity at Cencora</h2>
<ul>
<li>Eli Lilly, McKesson, Novartis Flash Promising Chart Action</li>
</ul>
<div class="lb-trans"><h2>Cencora 内部交易</h2>
<ul>
<li>艾礼礼、麦克森、诺华股价表现良好</li>
</ul>
</div><p>In other news, Director Dermot Mark Durcan acquired 500 shares of the stock in a transaction that occurred on Friday, May 24th. The shares were acquired at an average cost of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now owns 21,876 shares of the company's stock, valued at approximately $4,781,656.08. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. In other news, CEO Steven H. Collis sold 10,755 shares of the company's stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $63,323,746.56. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Dermot Mark Durcan purchased 500 shares of the firm's stock in a transaction dated Friday, May 24th. The shares were bought at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the transaction, the director now owns 21,876 shares of the company's stock, valued at $4,781,656.08. The disclosure for this purchase can be found here. In the last three months, insiders have sold 1,899,112 shares of company stock worth $408,654,376. Company insiders own 15.80% of the company's stock.</p>
<div class="lb-trans"><p>另外，董事 Dermot Mark Durcan 于 5 月 24 日星期五进行了一笔交易，购入了 500 股该公司的股票。这些股票的平均成本为每股 218.58 美元，总交易额为 109,290.00 美元。购买后，该董事现在持有公司股票的 21,876 股，价值约 4,781,656.08 美元。该交易已在提交给证券交易委员会的文件中披露，可通过此链接查看。此外，首席执行官 Steven H. Collis 于 7 月 16 日星期二出售了公司股票的 10,755 股。股票的平均价格为 222.12 美元，总交易额为 2,388,900.60 美元。出售后，首席执行官在公司中直接持有 285,088 股股票，价值 63,323,746.56 美元。该销售已在提交给证券交易委员会的文件中披露，可在此链接查看。此外，董事 Dermot Mark Durcan 于 5 月 24 日星期五购入了公司股票的 500 股。这些股票的平均价格为每股 218.58 美元，总交易额为 109,290.00 美元。交易完成后，该董事现在持有公司股票的 21,876 股，价值 4,781,656.08 美元。有关此次购买的披露信息，请点击此处。在过去的三个月中，内部人士已出售了价值 408,654,376 美元的 1,899,112 股公司股票。公司内部人士持有公司股票的比例为 15.80%。</p>
</div><h2>Institutional Investors Weigh In On Cencora</h2>
<div class="lb-trans"><h2>机构投资者对 Cencora 的看法</h2>
<p>对冲基金和其他机构投资者最近调整了他们对该股的持股。Fisher Asset Management LLC 在第四季度购入了 Cencora 股票的新头寸，价值约 244,000 美元。Vermont 信托公司在第四季度购入了 Cencora 股票的新头寸，价值约 62,000 美元。Wahed Invest LLC 在第四季度购入了 Cencora 股票的新头寸，价值约 567,000 美元。Vanguard Group Inc.在第四季度购入了 Cencora 股票的新头寸，价值约 4,212,508,000 美元。最后，Hennessy Advisors Inc.在第四季度购入了 Cencora 股票的新头寸，价值约 3,307,000 美元。目前，97.52% 的股份由机构投资者持有。</p>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the stock. Fisher Asset Management LLC bought a new position in shares of Cencora in the fourth quarter worth approximately $244,000. Trust Co. of Vermont bought a new position in shares of Cencora in the fourth quarter worth approximately $62,000. Wahed Invest LLC bought a new position in shares of Cencora in the fourth quarter worth approximately $567,000. Vanguard Group Inc. bought a new position in shares of Cencora in the fourth quarter worth approximately $4,212,508,000. Finally, Hennessy Advisors Inc. bought a new position in shares of Cencora in the fourth quarter worth approximately $3,307,000. 97.52% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><h2>Cencora 股票表现</h2>
<ul>
<li>3 家高股息房地产投资信托公司备受分析师看好</li>
</ul>
</div><h2>Cencora Stock Performance</h2>
<ul>
<li>3 High Dividend REITs That Analysts Are Bullish On</li>
</ul>
<div class="lb-trans"><p>该公司的市值为 493.8 亿美元，市盈率为 26.74，PEG 比率为 1.65，贝塔系数为 0.45。公司的 50 日移动平均价格为 228.28 美元，其两百日移动平均价格为 230.99 美元。公司的速动比率为 0.53，流动比率为 0.89，负债权益比率为 3.41。</p>
</div><p>The company has a market capitalization of $49.38 billion, a P/E ratio of 26.74, a PEG ratio of 1.65 and a beta of 0.45. The company's 50-day moving average is $228.28 and its two-hundred day moving average is $230.99. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所：COR - 获取免费报告）于 7 月 31 日星期三发布了最新的财报。该公司报告季度每股收益为 3.34 美元，超过了每股 3.18 美元的共识预期。该季度业务收入为 742.0 亿美元，而分析师预计为 733.2 亿美元。Cencora 的净资产回报率为 271.72%，净利润率为 0.65%。该季度 Cencora 的营收同比增长了 10.8%。在去年同期的同一季度，该公司每股收益为 2.92 美元。股票分析师预计，Cencora, Inc.在本财年将实现每股 13.47 美元的盈利。</p>
</div><p>Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 271.72% and a net margin of 0.65%. Cencora's revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.92 earnings per share. Equities analysts anticipate that Cencora, Inc. will post 13.47 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><h2>Cencora 股息宣布</h2>
<p>该公司最近宣布了季度股息，将于 8 月 26 日星期一支付。股东记录日期为 8 月 9 日星期五，将支付 0.51 美元的股息。这代表了每年 2.04 美元的股息和 0.82% 的收益率。该股息的除息日为 8 月 9 日星期五。Cencora 的股息支付比率目前为 22.32%。</p>
</div><h2>Cencora Dividend Announcement</h2>
<div class="lb-trans"><h2>Cencora 公司简介（获取免费报告）</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Monday, August 26th. Shareholders of record on Friday, August 9th will be paid a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Friday, August 9th. Cencora's dividend payout ratio is currently 22.32%.</p>
<h2>Cencora Company Profile (Get Free Report)</h2>
<p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc 是一家从事药品采购和分销的公司。该公司的美国医疗解决方案部门向急救医院、健康系统、独立和连锁零售药店、邮购药店、医疗诊所、长期护理和其他客户分发药品、非处方健康产品、家庭医疗用品和设备，以及相关服务；提供药房管理、人员配备和其他咨询服务；为零售和机构医疗服务提供供应管理软件；为各种机构和零售医疗服务提供包装解决方案；为生物技术和制药制造商提供临床试验支持、产品后批准和商业化支持服务、数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断试剂、微量饲料成分和其他产品；以及向制造商提供销售人员服务。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Cencora</li>
<li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li>
<li>Should You Invest in Bitcoin? Pros and Cons</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Shell Stock: Oil &amp; Gas Giant Committed to Buybacks and Dividends</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>五只我们比 Cencora 更喜欢的股票</li>
<li>房地产投资信托股票 - 今日应添加到您的投资组合中的最佳房地产投资信托股票</li>
<li>您应该投资比特币吗？利弊</li>
<li>投资于 5G 技术的热门股票</li>
<li>亚马逊股票在 AI 泡沫破裂后有望强劲反弹</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>壳牌股票：石油和天然气巨头致力于回购和派息</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Unveiled: NVIDIA’s &#34;Secret Royalty&#34; Program (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 揭秘：英伟达的&#34;秘密版税&#34;计划（来自市场幕后）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9039&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cencora right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 美元到 Cencora？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Cencora 之前，您应该听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票... 而 Cencora 不在这个名单上。</p>
</div><p>While Cencora currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Cencora 目前在分析师中有一个&#34;中等买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cencora（纽约证券交易所代码：COR）因分析师上调评级创下新的 12 个月高点